Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
Clin Gastroenterol Hepatol. 2013 Dec;11(12):1573-84.e1-2; quiz e88-9. doi: 10.1016/j.cgh.2013.07.034. Epub 2013 Aug 15.
BACKGROUND & AIMS: Liver stiffness measurement (LSM), using elastography, can independently predict outcomes of patients with chronic liver diseases (CLDs). However, there is much variation in reporting and consistency of findings. We performed a systematic review and meta-analysis to evaluate the association between LSM and outcomes of patients with CLDs.
We performed a systematic review of the literature, through February 2013, for studies that followed up patients with CLDs prospectively for at least 6 months and reported the association between baseline LSM and subsequent development of decompensated cirrhosis or hepatocellular carcinoma (HCC), as well as mortality. Summary relative risk (RR) estimates per unit of LSM and 95% confidence intervals (CIs) were estimated using the random effects model.
Our final analysis included 17 studies, reporting on 7058 patients with CLDs. Baseline LSM was associated significantly with risk of hepatic decompensation (6 studies; RR, 1.07; 95% CI, 1.03-1.11), HCC (9 studies; RR, 1.11; 95% CI, 1.05-1.18), death (5 studies; RR, 1.22; 95% CI, 1.05-1.43), or a composite of these outcomes (7 studies; RR, 1.32; 95% CI, 1.16-1.51). We observed considerable heterogeneity among studies-primarily in the magnitude of effect, rather than the direction of effect. This heterogeneity could not be explained by variations in study locations, etiologies and stages of CLD, techniques to measure liver stiffness, adjustment for covariates, or method of imputing relationship in the meta-analysis.
Based on a meta-analysis of cohort studies, the degree of liver stiffness is associated with risk of decompensated cirrhosis, HCC, and death in patients with CLDs. LSM therefore might be used in risk stratification.
使用弹性成像技术进行肝硬度测量(LSM)可独立预测慢性肝病(CLD)患者的结局。然而,报告和发现结果的一致性存在很大差异。我们进行了一项系统评价和荟萃分析,以评估 LSM 与 CLD 患者结局之间的相关性。
我们对文献进行了系统回顾,截至 2013 年 2 月,纳入前瞻性随访 CLD 患者至少 6 个月并报告 LSM 基线与随后发生失代偿性肝硬化或肝细胞癌(HCC)以及死亡率之间相关性的研究。使用随机效应模型计算每单位 LSM 的汇总相对风险(RR)估计值及其 95%置信区间(CI)。
我们的最终分析包括 17 项研究,共纳入 7058 例 CLD 患者。LSM 基线与肝功能失代偿(6 项研究;RR,1.07;95%CI,1.03-1.11)、HCC(9 项研究;RR,1.11;95%CI,1.05-1.18)、死亡(5 项研究;RR,1.22;95%CI,1.05-1.43)或这些结局的组合(7 项研究;RR,1.32;95%CI,1.16-1.51)的风险显著相关。研究间存在明显的异质性-主要表现为效应大小的差异,而非效应方向的差异。这种异质性无法通过研究地点、CLD 的病因和分期、测量肝硬度的技术、协变量的调整或荟萃分析中关系推断方法的差异来解释。
基于队列研究的荟萃分析,肝硬度程度与 CLD 患者失代偿性肝硬化、HCC 和死亡的风险相关。因此,LSM 可能用于风险分层。